ErSO against Breast cancer

A drug has been created that quickly kills up to 100% of breast tumor cells and metastases

Svetlana Maslova, Hi-tech+

The effect is achieved in a very short time and does not interfere with reproductive function. According to scientists, therapy can dramatically change the situation in the treatment of 75% of breast cancer cases.

Article by Boudreau et al. A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice is published in the journal Science Translational Medicine – VM.

A team from the University of Illinois at Urbana-Champaign presented the results of the experimental drug ErSO for the treatment of breast cancer. It targets estrogen receptor-positive cancer cells and does not harm healthy ones.

Since about 75% of all cancers are positive for estrogen receptors, ErSO can make a difference for the most common form of breast cancer. At the same time, ErSO has potential for other types of breast tumors, since it requires a small number of receptors to target, the authors explain.

Experiments on mouse models showed that the drug killed 95-100% of tumor cancer cells and metastases in bones, brain, liver and lungs.

Most often, the tumor shrank to an undetectable size in a week, but there were many cases when the tumor shrank by 99% in just three days. And even when a certain number of cancer cells remained in the body, provoking relapses, the tumors remained sensitive to repeated treatment.

It is known that tumor metastases are considered a key factor in the poor outcome of the disease. The astoundingly rapid action of ErSO against them most surprised scientists.

"Meanwhile, this is not another version of tamoxifen or fulvestrant, which are used to block the transmission of estrogen receptors in breast cancer," the authors emphasize. "Although it also binds to the estrogen receptor, it targets another part of it and attacks the protective cellular pathway of cancer."

It is important to note that the therapy did not disrupt the reproductive function of the animals. Scientists came to these conclusions after evaluating the effect of ErSO even in very high doses on models of rats, mice and dogs.

Further studies of ErSO, including clinical trials, will be conducted by the pharmaceutical company Bayer AG.

Portal "Eternal youth" http://vechnayamolodost.ru